Allergy Drops Side Effects vs Shots: A Safety Comparison

The most common side effects of sublingual allergy drops are local reactions in or around the mouth: itching or tingling of the lips, tongue, mouth, throat, or ears, mild swelling of the mouth or tongue, and occasional mild gastrointestinal upset such as stomach discomfort or nausea. Per a 2024 meta-analysis (Janz et al., 7,827 patients), local reactions occur in about 40.8% of users and are predominantly mild; in our program fewer than 0.1% of patients have systemic reactions. These local reactions are usually mild and transient, often easing over the first few weeks of treatment as tolerance develops. They reflect the allergen contacting the oral mucosa directly. While generally well tolerated, drops are not free of side effects, and any persistent or worsening symptoms should be reported to your provider.

The most common side effects of allergy shots are local reactions at the injection site: redness, swelling, warmth, and itching, which usually appear within hours and resolve on their own. These local reactions are frequent and generally minor. The more serious concern with shots is systemic reactions, which occur at a rate near 0.1% per injection and can range from hives and respiratory symptoms to, rarely, anaphylaxis. AAAAI surveillance attributes roughly one fatality per 2.5 million injections. This is precisely why allergy shots are administered in a clinic with a mandatory 30-minute observation period afterward, so that any systemic reaction can be treated immediately. The injection route's more direct systemic exposure explains this higher systemic-reaction risk compared with sublingual drops.

On systemic-reaction risk specifically, the evidence supports that drops carry a lower risk than shots. Sublingual reactions are predominantly mild and local, with anaphylaxis estimated at roughly one per 100 million doses and no fatalities reported worldwide; in our program fewer than 0.1% of patients have systemic reactions, while subcutaneous injections carry roughly 0.1% per injection visit with rare documented fatalities. This is an evidence-supported difference, not a marketing claim. However, drops are not absolutely safe — they commonly cause local oral reactions and carry their own contraindications, including eosinophilic esophagitis and uncontrolled asthma. The accurate framing is that drops have a lower risk of systemic reactions than shots, while both require appropriate screening, a prescribed epinephrine auto-injector, and provider guidance.

Anaphylaxis from sublingual allergy drops is exceptionally rare but not impossible. Estimates place the rate at roughly one per 100 million doses, and no SLIT fatalities have been reported worldwide, against an estimated very large number of doses administered globally. This stands in contrast to allergy shots, where systemic and rarely fatal reactions are better documented. Because the risk is not zero, patients on sublingual immunotherapy are typically prescribed an epinephrine auto-injector and counseled on warning signs. Certain situations, such as a severe reaction to a prior dose, intercurrent illness, or uncontrolled asthma, increase risk and should prompt contact with a provider. The exceptionally low but nonzero risk is why the first dose is supervised and why drops are not labeled as completely safe.

The difference reflects the systemic-reaction risk of each route. Allergy shots deliver allergen directly into the tissue beneath the skin, from which it reaches systemic circulation relatively quickly, creating a small but real chance of a systemic reaction in the minutes after injection. A 30-minute in-clinic observation period allows immediate treatment if that happens. Sublingual drops engage the tolerogenic oral mucosa with more limited and gradual systemic exposure, producing a much lower systemic-reaction rate, which supports at-home dosing after an initial supervised dose. This is the regulatory and clinical basis for the at-home model. Even so, sublingual users are prescribed epinephrine and instructed to watch for reactions, because the lower risk is not the same as no risk.